Effect of DN200434 on tumor growth in a sorafenib-resistant HCC xenograft model. (A-D) Representative images of an excised tumor (A), tumor weight (B), tumor volume (C), and body weight (D) of mice treated with sorafenib (10 mg/kg) in the presence/absence of DN200434 (10 mg/kg). Sorafenib-sensitive (SS) or –resistant (SR) Huh7 cells (6 × 106) cells were injected subcutaneously into the right flank of each mouse. Data are expressed as the mean ± SEM (n = 5 per group). (E-H) Representative image of excised tumor xenografts (E), tumor weight (F), tumor volume (G), and body weight (H) of mice treated with sorafenib (10 mg/kg) in the presence/absence of DN200434 (10 mg/kg). Sorafenib-sensitive (SS) or -resistant (SR) cells (6 × 106) were injected subcutaneously into the right flank of each mouse. Data are expressed as the mean ± SEM (n = 4 per group). N.S., not significant; **P < 0.01 and ***P < 0.001. Sora, Sorafenib; DN, DN200434.
